首页> 外文期刊>Acta Neuropathologica >Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein.
【24h】

Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein.

机译:脑膜血管周细胞瘤和孤立性纤维瘤携带NAB2-STAT6融合蛋白,可以通过STAT6蛋白的核表达来诊断。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Non-central nervous system hemangiopericytoma (HPC) and solitary fibrous tumor (SFT) are considered by pathologists as two variants of a single tumor entity now subsumed under the entity SFT. Recent detection of frequent NAB2-STAT6 fusions in both, HPC and SFT, provided additional support for this view. On the other hand, current neuropathological practice still distinguishes between HPC and SFT. The present study set out to identify genes involved in the formation of meningeal HPC. We performed exome sequencing and detected the NAB2-STAT6 fusion in DNA of 8/10 meningeal HPC thereby providing evidence of close relationship of these tumors with peripheral SFT. Due to the considerable effort required for exome sequencing, we sought to explore surrogate markers for the NAB2-STAT6 fusion protein. We adopted the Duolink proximity ligation assay and demonstrated the presence of NAB2-STAT6 fusion protein in 17/17 HPC and the absence in 15/15 meningiomas. More practical, presence of the NAB2-STAT6 fusion protein resulted in a strong nuclear signal in STAT6 immunohistochemistry. The nuclear reallocation of STAT6 was detected in 35/37 meningeal HPC and 25/25 meningeal SFT but not in 87 meningiomas representing the most important differential diagnosis. Tissues not harboring the NAB2-STAT6 fusion protein presented with nuclear expression of NAB2 and cytoplasmic expression of STAT6 proteins. In conclusion, we provide strong evidence for meningeal HPC and SFT to constitute variants of a single entity which is defined by NAB2-STAT6 fusion. In addition, we demonstrate that this fusion can be rapidly detected by STAT6 immunohistochemistry which shows a consistent nuclear reallocation. This immunohistochemical assay may prove valuable for the differentiation of HPC and SFT from other mesenchymal neoplasms.
机译:病理学家认为非中枢神经系统血管周细胞瘤(HPC)和孤立性纤维性肿瘤(SFT)是单个肿瘤实体的两个变体,现在归入实体SFT。最近在HPC和SFT中检测到频繁的NAB2-STAT6融合,为该视图提供了额外的支持。另一方面,当前的神经病理学实践仍然区分HPC和SFT。本研究着手鉴定参与脑膜HPC形成的基因。我们进行了外显子组测序,并在8/10个脑膜HPC的DNA中检测到NAB2-STAT6融合,从而提供了这些肿瘤与周围SFT密切相关的证据。由于外显子组测序需要大量的精力,我们试图探索NAB2-STAT6融合蛋白的替代标记。我们采用了Duolink邻近结扎法,并证明了17/17 HPC中存在NAB2-STAT6融合蛋白,而15/15脑膜瘤中不存在。更实际的是,NAB2-STAT6融合蛋白的存在在STAT6免疫组织化学中产生了强核信号。在35/37个脑膜HPC和25/25个脑膜SFT中检测到STAT6的核再分配,但在最重要的鉴别诊断中未检出87个脑膜瘤。未携带NAB2-STAT6融合蛋白的组织表现出NAB2的核表达和STAT6蛋白的细胞质表达。总之,我们为脑膜HPC和SFT构成由NAB2-STAT6融合定义的单个实体的变体提供了有力证据。此外,我们证明该融合可以通过STAT6免疫组织化学快速检测到,显示出一致的核再分配。这种免疫组织化学测定可能被证明对于区分HPC和SFT与其他间充质肿瘤很有价值。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号